Michael Campbell
Psychiatry · Honesdale, PANPI 1669684460
Payments from drug & device makers
Across 136 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$616
- Johnson & Johnson$359
- Teva Pharmaceuticals USA, Inc.$319
- Neurocrine Biosciences, Inc.$289
- Indivior Inc.$252
- AbbVie$140
- plus $393 from 10 others
What the payments were for
- Food & beverage$2,24195%
- Education$1265%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 34 | $616 |
| Johnson & Johnson | 23 | $359 |
| Teva Pharmaceuticals USA, Inc. | 17 | $319 |
| Neurocrine Biosciences, Inc. | 16 | $289 |
| Indivior Inc. | 15 | $252 |
| AbbVie(2 entities) | 7 | $140 |
| Sunovion Pharmaceuticals Inc. | 8 | $104 |
| Alkermes, Inc. | 4 | $85 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Sage Therapeutics, LLC | 2 | $41 |
| Novo Nordisk | 2 | $38 |
| Corium, LLC | 2 | $29 |
| Lundbeck LLC | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| GSK | 1 | $11 |
How this compares
$2,367 in reported general payments places this provider in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SublocadeBuprenorphine | 34 | $66,357 |
| Invega SustennaPaliperidone Palmitate | 22 | $54,564 |
| CaplytaLumateperone Tosylate | 16 | $26,806 |
| OzempicSemaglutide | 18 | $25,685 |
| LatudaLurasidone Hcl | 13 | $24,518 |
| Lurasidone Hcl | 82 | $22,285 |
| TrintellixVortioxetine Hydrobromide | 29 | $17,976 |
| Lisdexamfetamine Dimesylate | 48 | $12,268 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $8,159 |
| Clomipramine Hcl | 42 | $7,294 |
| Atomoxetine Hcl | 11 | $4,944 |
| Clozapine | 33 | $3,323 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 56 | $2,081 |
| Paliperidone ErPaliperidone | 18 | $2,078 |
| Buspirone Hcl | 83 | $1,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Sublocade | $252 | $66,35734 claims |
| Johnson & JohnsonInvega Sustenna | $359 | $54,56422 claims |
| Novo NordiskOzempic | $38 | $25,68518 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $104 | $24,51813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Honesdale
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.